Pfizer (NYSE:PFE) Stock Price Down 1.1% – What’s Next?

Pfizer Inc. (NYSE:PFE) fell 1.1% during mid-day trading on Thursday . The company traded as low as $26.46 and last traded at $26.4870. 71,762,459 shares traded hands during trading, an increase of 34% from the average session volume of 53,717,766 shares. The stock had previously closed at $26.78.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Q4 earnings beat — Pfizer reported better-than-expected revenue ($17.56B) and adjusted EPS above consensus, which supports near-term upside and underpins confidence in execution. Pfizer (PFE) Q4 2025 Earnings Call Transcript
• Positive Sentiment: Strong Phase 2b GLP‑1 obesity data — Pfizer’s MET‑097i (VESPER‑3) showed up to ~12.3% placebo-adjusted weight loss and maintained weight loss after dose transition, validating Pfizer’s entry into a large GLP‑1 market and creating a clear growth narrative. Pfizer (PFE) Announces Positive Phase 2b Results for Obesity Drug Showing 12.30% Weight Loss
• Neutral Sentiment: Mixed analyst stance — several shops keep “hold/neutral” ratings with modest upside targets, reflecting cautious optimism about pipeline upside offset by structural profit headwinds; these views limit immediate upgrades. Pfizer Stock Forecast: Trending Analysts See Cautious Upside
• Neutral Sentiment: FY‑2026 guidance is conservative-to-in-line — Pfizer updated EPS guidance to $2.80–$3.00 (consensus ~$2.97) and revenue guidance roughly in line but slightly wide; this reduces the immediacy of upside from near-term earnings beats while leaving room for pipeline-driven growth.
• Negative Sentiment: Pause on modRNA shingles work with BioNTech — the program hold signals some pipeline deprioritization and removes a potential longer‑term upside lever. Pfizer and BioNTech Pause modRNA Shingles Ambitions
• Negative Sentiment: Intense GLP‑1 competition — analysts and commentators note Pfizer faces entrenched leaders (Eli Lilly, Novo Nordisk). Commercial execution and later‑stage wins are required for material market share, so GLP‑1 excitement may be moderated by competitive risk. Can Pfizer Crash the Lilly and Novo Nordisk Weight-Loss Party?

Analyst Upgrades and Downgrades

A number of research firms have weighed in on PFE. Wolfe Research set a $24.00 price objective on Pfizer and gave the stock an “underperform” rating in a research report on Wednesday, December 17th. Morgan Stanley decreased their price target on Pfizer from $32.00 to $28.00 and set an “equal weight” rating on the stock in a research note on Friday, December 12th. HSBC reiterated a “buy” rating and issued a $29.00 price objective on shares of Pfizer in a research report on Wednesday, December 10th. BMO Capital Markets restated an “outperform” rating on shares of Pfizer in a research report on Wednesday, December 10th. Finally, Cantor Fitzgerald reiterated a “neutral” rating and issued a $27.00 price target on shares of Pfizer in a report on Wednesday. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Pfizer presently has a consensus rating of “Hold” and an average target price of $28.06.

Pfizer Trading Down 1.1%

The firm has a market cap of $150.60 billion, a PE ratio of 19.48 and a beta of 0.47. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.28 and a quick ratio of 0.97. The business has a 50-day moving average price of $25.57 and a two-hundred day moving average price of $25.07.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. The firm had revenue of $17.56 billion for the quarter, compared to analysts’ expectations of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.25%. The firm’s revenue was down 1.2% on a year-over-year basis. During the same period in the prior year, the company earned $0.63 EPS. Analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.5%. The ex-dividend date is Friday, January 23rd. Pfizer’s dividend payout ratio is 126.47%.

Institutional Trading of Pfizer

Several institutional investors and hedge funds have recently made changes to their positions in PFE. Passumpsic Savings Bank acquired a new position in Pfizer in the 4th quarter valued at about $618,000. North Dakota State Investment Board purchased a new stake in shares of Pfizer during the fourth quarter worth about $5,348,000. Roberts Glore & Co. Inc. IL raised its position in shares of Pfizer by 6.8% in the fourth quarter. Roberts Glore & Co. Inc. IL now owns 42,655 shares of the biopharmaceutical company’s stock valued at $1,062,000 after buying an additional 2,713 shares during the last quarter. Abacus Wealth Partners LLC purchased a new position in shares of Pfizer during the fourth quarter valued at approximately $854,000. Finally, L & S Advisors Inc acquired a new stake in Pfizer during the fourth quarter worth approximately $395,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.